Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable

International Clinical Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 283-290

  Duncan, Erica J ^a,b   Woolson, Sandra L ^c   Hamer, Robert M ^c  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

metabolic monitoring; risperidone; risperidone long acting injectable; treatment compliance

Indexed keywords

RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; VETERAN;

AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE ANTAGONISTS; DRUG MONITORING; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPENSITY SCORE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SOUTHEASTERN UNITED STATES; VETERANS HEALTH;

EID: 84864676108     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328354b534     Document Type: Article

References (13)

1. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 pp. 596-601.
2. Brown WV, Jacobson TA (2000). The management of lipoprotein disorders. In: Branch WT, Alexander RW, Schlant RC, Hurst JW, editors. Cardiology in primary care. New York: MacGraw-Hill Companies. pp. 201-222.
3. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. (2005). Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15:111-117. (Pubitemid 39574406)
4. Dunlop BW, Sternberg M, Phillips LS, Andersen J, Duncan E (2003). Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull 37:99-117.
5. Expert Committee (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:S5-S20.
6. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132. (Pubitemid 41070972)
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
8. Lindenmayer J-P, Eerdekens L, Berry S, Eerdekens M (2004). Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, openlabel study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65:1084-1089.
9. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S (2007). Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 17:138-144. (Pubitemid 44779189)
10. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349. (Pubitemid 38989085)
11. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1-93. (Pubitemid 40677047)
12. Newcomer JW, Haupt DW (2006). The metabolic effects of antipsychotic medications. Can J Psychiatry 51:480-491. (Pubitemid 44166336)
13. Schmauss M, Sacchetti E, Kahn JP, Medori R, Schmauss M, Sacchetti E, et al. (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 22:85-92.